MX2025001965A - Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer - Google Patents
Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancerInfo
- Publication number
- MX2025001965A MX2025001965A MX2025001965A MX2025001965A MX2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A MX 2025001965 A MX2025001965 A MX 2025001965A
- Authority
- MX
- Mexico
- Prior art keywords
- mta
- treatment
- cooperative
- cancer
- prmt5 inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02028—S-Methyl-5'-thioadenosine phosphorylase (2.4.2.28)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91091—Glycosyltransferases (2.4)
- G01N2333/91142—Pentosyltransferases (2.4.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente memoria descriptiva se refiere a métodos de tratamiento de cánceres con el gen MTAP natural que comprenden administrar un inhibidor de PRMT5 sinérgico con MTA a un paciente que lo necesita.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263397996P | 2022-08-15 | 2022-08-15 | |
| PCT/EP2023/072364 WO2024038004A1 (en) | 2022-08-15 | 2023-08-14 | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2025001965A true MX2025001965A (es) | 2025-04-02 |
Family
ID=87748037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025001965A MX2025001965A (es) | 2022-08-15 | 2025-02-17 | Inhibidores de prmt5 cooperativos con mta para uso en el tratamiento del cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20260048040A1 (es) |
| EP (1) | EP4572760A1 (es) |
| JP (1) | JP2025528186A (es) |
| KR (1) | KR20250048049A (es) |
| CN (1) | CN119730853A (es) |
| AU (1) | AU2023327684A1 (es) |
| CA (1) | CA3263923A1 (es) |
| IL (1) | IL318816A (es) |
| MX (1) | MX2025001965A (es) |
| TW (1) | TW202423435A (es) |
| WO (1) | WO2024038004A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| WO2026114356A1 (zh) * | 2024-11-29 | 2026-06-04 | 普罗思特(南京)生物科技有限公司 | 含氮杂环化合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3160958T3 (da) | 2014-06-25 | 2021-04-12 | Glaxosmithkline Ip Dev Ltd | Krystallinske salte af (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidin-4-carboxamid |
| CN120208880A (zh) * | 2019-09-12 | 2025-06-27 | 米拉蒂医疗股份有限公司 | Mta-协同prmt5抑制剂 |
| US12403137B2 (en) | 2019-10-28 | 2025-09-02 | Tango Therapeutics, Inc. | Compounds and methods of use |
| MX2022010011A (es) | 2020-02-12 | 2022-10-18 | Amgen Inc | Inhibidores de prmt5 novedosos. |
| CN116568677B (zh) | 2020-07-31 | 2026-07-28 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
| EP4251624B1 (en) | 2020-11-24 | 2025-10-29 | Amgen Inc. | Tricyclic carboxamide derivatives as prmt5 inhibitors |
| LT4263545T (lt) | 2020-12-16 | 2026-07-27 | Amgen Inc. | Prmt5 inhibitoriai |
| RU2757957C1 (ru) | 2020-12-30 | 2021-10-25 | Александр Григорьевич ВИЛЛЕР | Роботизированная система и способ проведения эндоваскулярной хирургической операции |
| CN117062816A (zh) | 2021-02-04 | 2023-11-14 | 美国安进公司 | 三环-酰胺-双环prmt5抑制剂 |
| EP4304720A1 (en) | 2021-03-11 | 2024-01-17 | Mirati Therapeutics, Inc. | Mta-cooperative prmt5 inhibitors |
| US20240368153A1 (en) | 2021-07-02 | 2024-11-07 | Mirati Therapeutics, Inc. | Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors |
| EP4402143A1 (en) | 2021-09-13 | 2024-07-24 | Astrazeneca AB | Spirocyclic compounds |
| KR20240157631A (ko) | 2021-11-05 | 2024-11-01 | 미라티 테라퓨틱스, 인크. | Prmt5 저해제로서 2-아미노 이미다졸 유도체 |
| EP4442680A4 (en) | 2021-11-30 | 2026-05-06 | Abbisko Therapeutics Co Ltd | Pyrazole derivative, its preparation process and its use in medicine |
| CN116462677A (zh) | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
| CN116462676A (zh) | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
| CN116178347B (zh) | 2022-06-29 | 2025-07-04 | 苏州浦合医药科技有限公司 | Prmt5-mta抑制剂 |
-
2023
- 2023-08-14 WO PCT/EP2023/072364 patent/WO2024038004A1/en not_active Ceased
- 2023-08-14 CA CA3263923A patent/CA3263923A1/en active Pending
- 2023-08-14 AU AU2023327684A patent/AU2023327684A1/en active Pending
- 2023-08-14 US US19/103,402 patent/US20260048040A1/en active Pending
- 2023-08-14 JP JP2025507748A patent/JP2025528186A/ja active Pending
- 2023-08-14 EP EP23757579.0A patent/EP4572760A1/en active Pending
- 2023-08-14 CN CN202380059404.5A patent/CN119730853A/zh active Pending
- 2023-08-14 IL IL318816A patent/IL318816A/en unknown
- 2023-08-14 KR KR1020257006835A patent/KR20250048049A/ko active Pending
- 2023-08-15 TW TW112130596A patent/TW202423435A/zh unknown
-
2025
- 2025-02-17 MX MX2025001965A patent/MX2025001965A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023327684A1 (en) | 2025-03-20 |
| US20260048040A1 (en) | 2026-02-19 |
| EP4572760A1 (en) | 2025-06-25 |
| KR20250048049A (ko) | 2025-04-07 |
| CA3263923A1 (en) | 2024-02-22 |
| JP2025528186A (ja) | 2025-08-26 |
| WO2024038004A1 (en) | 2024-02-22 |
| IL318816A (en) | 2025-04-01 |
| TW202423435A (zh) | 2024-06-16 |
| CN119730853A (zh) | 2025-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004215A (es) | Terapias combinadas de inhibidores de kras g12d con inhibidores de sos1. | |
| JOP20250258A1 (ar) | مثبطات 2-آزا باي سيكلو هبتان kras | |
| MX2023015236A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y sus usos para el tratamiento de cancer. | |
| MX2024009727A (es) | Terapias de combinacion. | |
| MX2025003821A (es) | Compuestos con actividad contra tumores mutantes de kras | |
| MX2022009347A (es) | Terapia de combinacion para el tratamiento del crecimiento celular anormal. | |
| SA522431915B1 (ar) | Prmt5 مثبطات mta تعاونية مع | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| WO2021243280A3 (en) | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 | |
| MX2024004213A (es) | Combinaciones de inhibidores de kras g12d con inhibidores de pi3ka y métodos de tratamiento relacionados. | |
| Shah et al. | Granulomatous slack skin disease: a review, in comparison with mycosis fungoides | |
| JOP20210317A1 (ar) | مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان | |
| WO2020205473A8 (en) | Compositions and methods for the treatment of kras associated diseases or disorders | |
| CR20210409A (es) | Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer | |
| EP4512480A3 (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| MX2023011856A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. | |
| MY183661A (en) | Treatment of cancer with tor kinase inhibitors | |
| EP4389225A3 (en) | Cancer treatments using combinations of type 2 mek and erk inhibitors | |
| TN2010000204A1 (en) | Kinesin inhibitors as cancer therapeutics | |
| MX2009007777A (es) | Terapia de combinacion que comprende romidepsina y bortezomib. | |
| MX2024004214A (es) | Combinaciones de inhibidores de kras g12d con irinotecán y métodos de tratamiento relacionados. | |
| MX2025003908A (es) | Compuesto inhibidor de parg | |
| JOP20250150A1 (ar) | علاجات السرطان باستخدام مثبطات prmt5 التعاونية مع mta | |
| MX2025014397A (es) | Inhibidores de helicasa de adn recq del sindrome de werner (wrn) |